Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Colloids Surf B Biointerfaces. 2022 Dec 19;222:113103. doi: 10.1016/j.colsurfb.2022.113103

Figure 5.

Figure 5.

Cytotoxicity of CRISPR/Cas9 targeted liposomal formulations in brain endothelial bEND.3 cells. Data represent the mean±SD, n=6-8 (F1: 6 ng CRISPR/Cas9 plasmid with 1:1 ratio of plasmid phosphate groups and cationic lipids; F2: 12 ng CRISPR/Cas9 plasmid with 1:1 ratio of plasmid phosphate groups and cationic lipids; F3: 24 ng CRISPR/Cas9 plasmid with 1:1 ratio of plasmid phosphate groups and cationic lipids; F4: 48 ng CRISPR/Cas9 plasmid with 1:1 ratio of plasmid phosphate groups and cationic lipids; F5: 6 ng CRISPR/Cas9 plasmid with 1:2 ratio of plasmid phosphate groups and cationic lipids; F6: 12 ng CRISPR/Cas9 plasmid with 1:2 ratio of plasmid phosphate groups and cationic lipids; F7: 24 ng CRISPR/Cas9 plasmid with 1:2 ratio of plasmid phosphate groups and cationic lipids; F8: 48 ng CRISPR/Cas9 plasmid with 1:2 ratio of plasmid phosphate groups and cationic lipids; F9: 6 ng CRISPR/Cas9 plasmid with 1:3 ratio of plasmid phosphate groups and cationic lipids; F10: 12 ng CRISPR/Cas9 plasmid with 1:3 ratio of plasmid phosphate groups and cationic lipids; F11: 24 ng CRISPR/Cas9 plasmid with 1:3 ratio of plasmid phosphate groups and cationic lipids; F12: 48 ng CRISPR/Cas9 plasmid with 1:3 ratio of plasmid phosphate groups and cationic lipids).